cetuximab,afatinib,pembrolizumab,adagrasib
mirati,boehringer ingelheim,eli lilly,merck
['gi ', 'cetuximab', 'krystal-1', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'adagrasib']
interesting data presented at the lower gi session chaired by and during #esmo22 by : #krystal-1: updated efficacy and safety of #adagrasib w/ or w/o #cetuximab in advanced #crc with krasg12c mutation! 
(Young) Medical oncologist